Clinical Trials


Image of Exam Room in 9U Prevention Center

  1. Akcea
    The study is designed to evaluate the effect of a novel agent (IP-Isis 681257) on the plasma level of LP(a), which is has been recognized as an independent, genetically mediated, causal risk factor for coronary artery disease (CAD), stroke, peripheral arterial disease (PAD), and calcific aortic stenosis. As a phase II study it will evaluate pharmacokinetics (PK) of ISIS 681257 across different doses and dose regimens in in patients with elevated levels of LP(a) and established CVD. We are part of this study which will involve approximately 140 patients, who were randomized in a 4:1 ratio (112 ISIS 681257 and 28 placebo) to receive ISIS 681257 or placebo. The study drug (ISIS 681257 or placebo) will be administered SC every week or every 4 weeks, (depending on cohort assignment), for up to 52 weekly doses or up to 13 every-4-week doses. We believe this is an important trial because of the mounting information on the importance of LP(a) as a significant risk factor for the development of cardiovascular disease.
  2. VAPOR: Vascular Effects of Ambient Exposure to Vehicular Air Pollution
    This pilot study investigates the vascular effects of exposure to vehicular air pollution. Blood and ultrasound measures of cardiovascular health will be compared within subjects (before and after exposure to air pollution) and between subjects. This study will contribute to the growing understanding of environmental exposures as modifiable risk factors for CVD.
  3. TACT2: Trial to Assess Chelation Therapy 2 
    A multi-site 2x2 factorial randomized placebo-controlled trial of Na2EDTA chelation therapy. Participants receive 40 ~weekly infusions and take high-dose multivitamin/multimineral or placebo pills at home. The trial will also test the hypothesis that chelation’s effects on cardiovascular health are mediated by removal of heavy metals from the body.
  4. Platelet Activity and Thrombosis Registry & Prevention Biorepository
    A prospective registry of patients with early cardiovascular disease. A biorepository of platelet activity, platelet RNA, whole blood RNA and DNA is being stored in all individuals. This repository will enable us to better understand potential mechanisms of early onset of cardiovascular disease.
  5. PACE Trial: Platelet Activity in Vascular Surgery and Cardiovascular Events
    A prospective study to assess the association between platelet activity in subjects before and after vascular surgery with incident cardiovascular and bleeding events. Pathological and clinical studies have consistently demonstrated that abnormalities in platelet activity play a major role in the pathogenesis of atherosclerosis and atherothrombosis. Screening for abnormalities in thrombosis and hemostasis by measuring platelet activity, thrombin generation, and markers of coagulation have been proposed to identify individuals at high-risk for cardiovascular events, however, it remains a research tool not ready for implementation in standard care. This study will add to the growing understanding of platelet activity and markers of coagulation in cardiovascular disease; examine a comprehensive battery of platelet activity markers, markers of coagulation, and inflammatory biomarkers in subjects undergoing vascular surgery; and will provide important data on the mechanism of increased platelet activity using mRNA and microRNA expression profiling.
  6. TwoSPECIFIc
    This research project explores a potential pathophysiologic link between obesity, HDL function and thrombosis by examining how two types of bariatric surgery – Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) – affect (1) platelet function and gene expression in morbidly obese individuals, and (2) the in vitro effect of HDL on platelet aggregation and platelet precursor gene expression.


  1. ODYSSEY DM-Dyslipidemia Clinical Trial Program
    We enrolled patients in a study that tests alirocumab, approved for lowering “bad” cholesterol (LDL) in diabetic patients. The medication, , has already been approved by the FDA for patients with or at risk of heart disease. This particular clinical trial is for patients who have type 2 diabetes and high LDL cholesterol levels not adequately controlled by statin treatment. Patients should be on a stable regimen of glucose lowering treatments for type 2 diabetes and taking a statin medication (or cannot take a statin) without other cholesterol lowering treatments. Please contact the study for further information at 646-501-0244.
    The primary objective of the study was to compare the effect of alirocumab with placebo on the occurrence of cardiovascular events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization) in patients who experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and are treated with evidence-based medical and dietary management of dyslipidemia.
  3. Antiplatelet Therapy HIV
    We are investigating why subjects with HIV are at higher risk for heart disease, and more specifically, can the study of platelets and their manipulation via platelet inhibiting drugs (aspirin versus clopidogrel) improve platelet function and immune function in those with active HIV.
  4. HONOR Trial: Patient Centered Home Exercise Program for Peripheral Artery Disease
    We were a site for a Patient Centered Outcomes Research Institute (PCORI) funded randomized controlled trial testing whether a home-based exercise program significantly improves walking performance and other patient-centered outcomes in patients with peripheral arterial disease, compared to usual care.
  5. EMERALD-D study: Environmental Exposures and Cardiovascular Disease in Diabetes
    A cross-sectional study with an optional follow-up repository timed with clinical labs for diabetes, this study investigated the vascular effects of environmental exposure among patients with diabetes and establish a biorepository to explore novel CVD risk factors among patients with diabetes,contributing to the growing understanding of environmental exposures as modifiable risk factors for CVD.
  6. Effects of bariatric surgery on platelet characteristics and function
    We examined platelet-specific activity and inflammatory gene expression prior to and following weight loss surgery in obese patients, a group that is at increased risk for thrombosis. This study provides data on platelet-specific changes which occur following bariatric surgery.
    Reduce-it is a prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of AMR101 (EPA only fish oil) on cardiovascular health and mortality.Nine patients have enrolled to date and the study is closed.
    This study assess the effect of ertugliflozin as compared with non-erthugliflozin comparator group on the time to first occurrence of fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, hospitalization for a primary diagnosis of heart failure, individual components of MACE plus (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina). Nine patients enrolled at NYU, and the study is closed to accrual at this time.
  9. Pivotal Trial: Platelet Activity in Vascular Surgery – Thrombosis and Bleeding
    This study focuses on patients with vascular disease in different arterial territories, including peripheral artery disease, carotid artery disease, abdominal aortic aneurysm. We measure platelet activity and cardiovascular risk before and after vascular surgery.
  10. Platelet Activity in Cardiovascular Disease
    The purpose of this study is to examine platelet activity in patients with cardiovascular disease compared to a normal healthy control population.
  11. Effect of bariatric surgery on HDL function in cholesterol efflux in obese women with and without the metabolic syndrome
    This study assesses the effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on HDL cholesterol efflux capacity.
  12. IMPACT
    The Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) aims to determine the best management strategy for patients undergoing cardiovascular intervention. IMPACT was a prospective randomized trial with 400 patients post-cardiovascular intervention enrolled. The studycompared different cardiovascular prevention strategies of usual care, cardiovascular prevention consult, or a motivational interviewing program with tailored text messaging over a 6-month period. The primary endpoint will be non-HDL cholesterol. Secondary endpoints include other lipid values, metabolic risk, smoking cessation, physical activity, nutritional status, and quality of life. IMPACT is funded by a grant from the Rainer Arnhold Foundation and enrollment begun in the spring of 2012. 400 enrolled in this trial.
    This randomized phase III trial evaluates the efficacy on antisense oligonucleotide (ASO) drug ISIS 304801 (300 mg once weekly) in patients with familial chylomicronemia syndrome (FCS) as compared to placebo in reducing fasting triglycerides, risk of developing pancreatitis, and other symptoms of FCS. This drug inhibits liver production of apoC-III. We will enroll a small number of patients (10>) with this rare metabolic condition. The patients will be screened for genetic defects in lipoprotein lipase and will have their lipoprotein lipase enzyme measured in postheparin blood.
  14. TECOS
    The TECOS trial evaluated the cardiovascular effects of sitagliptin. Subjects included those with a diagnosis of type II diabetes, 50 years of age or greater, and on medications or insulin to lower blood sugar. The study's primary objective was to compare the impact of including sitagliptin as part of usual care vs. usual care without sitagliptin on cardiovascular outcomes.
    SOLID examines the effects of Darapladib on the stabilization of plaques in a high risk patient population less than 30 days post-ACS. Subjects enrolled in this study met at least one of the following criteria: at least 60 years of age, history of prior MI, taking diabetes required medication, GFR between 30 and 59, or diagnosed with PAD and/or CVD.
    The STABILITY is double-blind, randomized trial that evaluated the stabilization of atherosclerotic plaque by initiation of Darapladib therapy. In order to be enrolled, subjects had to have documented chronic heart disease with an additional predictor of cardiovascular risk.